Heparin, an anticoagulant or blood-thinning compound, is most commonly used during thrombosis treatment. The heparin market in Europe is currently in the midst of renewed growth with imports of heparin from China having been recently heavily curbed. Transparency Market Research, a leading business intelligence firm based in the United States, says that the Europe heparin market will grow from its 2013 valuation of US$2,004.5 million to US$3,148.0 million by the end of 2022. Expressed in CAGR, this translates to 5.2% between 2014 and 2022.
Countries that constitute a bulk of the heparin market in Europe are Germany, France, United Kingdom, Spain and Italy. Here’s a closer look at the factors that will drive the heparin market in major European countries over the next seven years:
Germany – The Largest Heparin Market in Europe
With a Heparin market amounting to US$274.8 million as of 2013, Germany stands as the leader in the European space. The heparin market in Germany faces several factors that are conducive to growth – right from a high prevalence of VTE to the banning of Chinese active pharmaceutical ingredients (APIs) to more companies entering the Heparin processing business. Over the next few years, the growth of the heparin market in Germany is expected to remain promising. The most notable trend here is meat processing companies diversifying their business to include heparin processing in their portfolio – a case in point would be the Tönnies Group that purchased Pharma Action to foray into heparin manufacturing/processing.
Browse The Market Research Report on Europe Heparin Market:
France – High VTE-Related Deaths Stir Heparin Market
France is the second-largest heparin market in Europe. In France, VTE related deaths amount to approximately 370,000 annually. This aspect has helped the expansion of the heparin market in France. As compared to other countries such as Spain, Italy and the United Kingdom, patients are administered more heparin during surgical procedures such as breast surgeries, knee replacement, and appendectomy, and hip surgeries. Many patients are also advised to regularly take heparin during convalescence.
Another factor that underpins the growth of the heparin market in France is the increasing percentage of aging population – recent studies estimate that one fourth of the population would be aged 60 years or over by 2020.
The United Kingdom – Use of Heparin for Prophylaxis and Thrombosis Treatment Creates Window of Opportunity
The Thrombosis Research Institute’s findings state that England reports the death of about 25,000 people per from hospital-contracted VTE. The country’s Department of Health, which had published an operating framework for the National Health Service (NHS), requires that thrombosis risk assessment needs to be conducted in no less than 90% of patients admitted to a hospital. This factor will augurs well for the growth of the heparin market in the UK, especially as the number of people undergoing treatment for thrombosis rises. The UK represents the third largest heparin market in Europe.
Browse The Press Release of Europe Heparin Market:
Other major European countries such as Spain and Italy will also report a rise in the size of the heparin market owing to factors that are similar to the three countries mentioned above. However, market players will need to find ways to bypass growth roadblocks such as the availability of synthetically-formulated heparin that’s more cost-effective and easily procurable.